Macustar UK
Research type
Research Study
Full title
Development of novel clinical endpoints for interventional clinical trials with a regulatory and patient access intention in patients with intermediate age-related macular degeneration (AMD) - MACUSTAR
IRAS ID
237357
Contact name
Maeve McGovern
Contact email
Sponsor organisation
University of Bonn, Germany
Clinicaltrials.gov Identifier
Duration of Study in the UK
3 years, 11 months, 28 days
Research summary
Age related macular degeneration (AMD) is the commonest cause of visual loss in Europe, it causes progressive loss of central vision. There are 2 forms of the disease 'Wet' and 'Dry'. At present we only have treatment for the late ‘wet’ form, we do not have treatments for the early wet form (which is much more common) or for the late ‘dry’ manifestations. Thus, it is important to develop interventions for early forms of AMD. In order to do this we need to find the most appropriate tools to implement and analyze the efficacy of interventions in clinical trials of AMD. We hope that the MACUSTAR study will provide these much needed tools.
MACUSTAR combines Europe’s most relevant clinical and scientific expertise in a group which includes 20 designated clinical sites across seven countries in Europe.
750 subjects will be recruited at 20 clinical sites from seven EU countries (Denmark, France, Germany, Italy, Portugal, Netherlands and United Kingdom). There will be 3 sites in the UK. Each site will recruit 30-40 subjects .REC name
London - Queen Square Research Ethics Committee
REC reference
18/LO/0145
Date of REC Opinion
20 Mar 2018
REC opinion
Further Information Favourable Opinion